The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy ; volume:15 ; number:1 ; day:3 ; month:11 ; year:2017 ; pages:1-10 ; date:12.2017
Journal of translational medicine ; 15, Heft 1 (3.11.2017), 1-10, 12.2017
- Creator
-
Masucci, Giuseppe V.
- Contributor
-
Cesano, Alessandra
Eggermont, Alexander
Fox, Bernard A.
Wang, Ena
Marincola, Francesco M.
Ciliberto, Gennaro
Dobbin, Kevin
Puzanov, Igor
Taube, Janis
Wargo, Jennifer
Butterfield, Lisa H.
Villabona, Lisa
Thurin, Magdalena
Postow, Michael A.
Sondel, Paul M.
Demaria, Sandra
Agarwala, Sanjiv
Ascierto, Paolo A.
SpringerLink (Online service)
- DOI
-
10.1186/s12967-017-1325-2
- URN
-
urn:nbn:de:101:1-2018090514201080414656
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Masucci, Giuseppe V.
- Cesano, Alessandra
- Eggermont, Alexander
- Fox, Bernard A.
- Wang, Ena
- Marincola, Francesco M.
- Ciliberto, Gennaro
- Dobbin, Kevin
- Puzanov, Igor
- Taube, Janis
- Wargo, Jennifer
- Butterfield, Lisa H.
- Villabona, Lisa
- Thurin, Magdalena
- Postow, Michael A.
- Sondel, Paul M.
- Demaria, Sandra
- Agarwala, Sanjiv
- Ascierto, Paolo A.
- SpringerLink (Online service)
Other Objects (12)
What have we learned from cancer immunotherapy in the last 3 years?
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
What have we learned from cancer immunotherapy in the last 3 years?
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
What have we learned from cancer immunotherapy in the last 3 years?
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021